肝益方治疗原发性肝癌介入术后34例疗效观察

Clinical Observation on the Effect of the Treatment of 34 Primary Liver Cancer Patients after Interventional Treatment with Ganyi Prescription

目的:观察肝益方治疗原发性肝癌介入术后,中医辨证属肝肾阴虚兼脾气虚证患者的临床疗效。方法:54例患者分为治疗组34例、对照组20例。治疗组肝动脉化疗栓塞(TACE)后服用肝益方,对照组TACE后服VitC等。通过观察患者临床总证候、临床症状、生活质量(KPS)评分、外周血T细胞亚群、NK细胞比例、肝功能、血常规变化以及安全性观察明确该方临床疗效。结果:肝益方临床总证候治疗有效率优于对照组(P<0·05),对口干、盗汗、纳呆、便溏症状的改善优于对照组(P<0·05),可明显提高患者生活质量(P<0·05),明显上调患者CD4+T淋巴细胞,NK细胞比例(P<0·05),提高血小板数量,该方无毒副反应。结论:肝益方配合介入治疗原发性肝癌可显著提高诊治该病的临床疗效。

Objective: To observe the clinical effectiveness of the treatment of the patients suffering from yin deficiency in liver and kidney and deficiency in spleen and treated by interventional treatment of primary liver cancer. Methods: 54 patients were divided into one test group with 34 patients and one control group with 20 patients at random sample. The test group was treated with Ganyi prescription after the use of TACE while the control group was treated with VitC after the use of TACE. Results: The rate of the total effectiveness of the test group was superior to that of the control group (P<0.05). The improvement of the dry mouth, night sweat, anorexia, loose stool of the test group was superior to that of the control group (P<0.05), obviously improving the quality of life of the patients (P<0.05), raising CD4'T lymphocyte of the patients. The rate of NK cells (P<0.05) increased the number of blood platelet. Ganyi prescription showed no toxic and side effect. Conclusion: Ganyi prescription coordinated with the interventional treatment of primary liver cancer may obviously improve the clinical effectiveness of the disease.